Torisel action delayed
Executive Summary
FDA extends its review of Wyeth's renal cell carcinoma agent to evaluate recently-submitted tumor data, the firm says April 6. The three-month delay sets a July 5 estimated user fee date for temsirolimus. If approved, Torisel would compete with Bayer's Nexavar and Pfizer's Sutent...